Implanet reported its sales from the third quarter, ending Sept. 30, as well as total sales for the first nine months of 2016.
Here are eight highlights:
1. Implanet saw total sales of €5.58 million over the first nine months of the year. This number reflects a 12 percent increase over the same time period last year.
2. The France market witnessed a 37 percent increase in sales to €2.86 million in the first nine months of 2016, and the U.S. market saw a 53 percent increase to €1.55 million.
3. The company had 66 surgeon users in the United States and 51 surgeon users in France, as of Sept. 30.
4. Implanet's spine activity increased by 27 percent in the first nine months of 2016 compared to last year, hitting €2.86 million.
5. The company's knee activity decreased 1 percent to €2.71 million in the first nine months of the year, compared to the same time period in 2015.
6. Implanet saw sales of €1.48 million in the third quarter, down 12 percent compared to the third quarter of 2015. This decrease is due to knee implant deliveries being postponed in Brazil.
7. In the third quarter, Implanet's spine activity increased to €848,000.
8. In the third quarter, the company sold 340 JAZZ units in the United States, 824 in France and 341 in the rest of the world, representing a 22 percent growth by volume.
"This was the company's second most successful quarter in spine activity. On the adult degenerative bone disorder segment, which is acyclic and has substantial potential given the large number of annual procedures, we generated growth of 145 percent over third quarter 2015 and +140 percent over the first nine months of the year," said Ludovic Lastennet, CEO, Implanet.